AZD2066 Cocktail Study
CompletedPhase 1NCT00930306
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The aims of this study are to examine the effect of repeated doses of AZD2066 and of caffeine, bupropion, tolbutamide, omeprazole, metoprolol and midazolam on the blood concentrations of each other
Study details
- Official title
- A Phase I, Open Label, Multi Centre Study in Healthy Volunteers to Estimate the Effect of Multiple Doses of AZD2066 on the Activity of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 by Administering a Cocktail of Caffeine, Bupropion, Tolbutamide, Omeprazole, Metoprolol and Midazolam
- Conditions
- Interventions
- Drug: AZD2066
- Drug: Caffeine
- Drug: Tolbutamide
- Drug: Omeprazole Tablet, 20 mg
- Drug: Midazolam Tablet, 7.5 mg
- Sponsor
- AstraZeneca
- Start date
- 2009-06
- Sex
- All
- Age range
- from 18 Years to 60 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures * Healthy volunteers with BMI between 18 and 30 kg/m2 * Medical and surgical history and physical examination without any clinically significant findings * Non smokers or past smokers who have stopped smoking within the last 6 months. Exclusion Criteria: * History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, personality disorder or other significant psychiatric disorders or any other major disorder that may interfere with the objectives of the study, as judged by the Investigator * Clinically significant illness as judged by the Investigator, within four weeks before the first administration of investigational product. * Female subjects who have a positive pregnancy test or who are pregnant or breast-feeding
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00930306